Business Context and Reporting Period
Company: Henry Schein, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 26, 2005
Business Overview: Henry Schein is the largest distributor of healthcare products and services to office-based practitioners in North America and Europe. Operations are conducted through two segments: Healthcare Distribution (dental, medical, and international) and Technology (practice management software and services). The company serves over 475,000 customers globally.
Key Financial Metrics
| Metric | Q1 2005 | Q1 2004 |
|---|---|---|
| Net Sales | $1,101.4 million | $886.6 million |
| Gross Profit | $306.2 million | $230.8 million |
| Gross Margin | 27.8% | 26.0% |
| Operating Income | $57.2 million | $46.3 million |
| Net Income | $33.2 million | $28.4 million |
| Diluted EPS | $0.37 | $0.31 |
| Cash and Equivalents | $114.7 million | $73.1 million |
| Total Debt | $526.9 million | $535.6 million |
| Working Capital | $756.6 million | $736.8 million |
Cash Flow Summary (Three Months Ended March 26, 2005):
- Net cash used in operating activities: $(15.3) million
- Net cash used in investing activities: $(54.0) million
- Net cash used in financing activities: $(6.3) million
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 24.2% year-over-year. This was driven by 23.1% local currency growth (7.5% organic, 15.6% from acquisitions) and 1.1% foreign currency impact.
- Segment Performance:
- International: Sales surged 72.3% primarily due to the acquisition of the Demedis Group (66.6% of growth).
- Dental: Sales grew 21.9%, aided by new distribution agreements (Colgate and Pentron) and acquisitions.
- Medical: Sales increased 3.6%, entirely from internal volume growth.
- Profitability: Gross margin expanded to 27.8% from 26.0%, reflecting a strategic shift away from lower-margin pharmaceutical and veterinary customers. Operating income rose 23.5%.
- Expenses: Selling, general, and administrative (SG&A) expenses increased 34.9% to $249.0 million, rising as a percentage of sales from 20.8% to 22.6% due to payroll increases and acquisition-related costs.
- Acquisitions: The company acquired Ash Temple Limited (Canada) in January 2005 and completed three other smaller acquisitions. Regulatory approval was received in April 2005 for the pending acquisition of the Demedis Group's Austrian business (Austrodent).
Outlook, Risks, and Contingencies
Management Commentary & Guidance:
- Influenza Vaccine: The company is the primary U.S. distributor for Chiron's Fluvirin vaccine. While Chiron's manufacturing license suspension was lifted in March 2005, uncertainty remains regarding the volume of doses available for the 2005 season. Henry Schein has secured a multi-year agreement with ID Biomedical to distribute Fluviral vaccine, potentially starting in 2006.
- Capital Allocation: The company expects to invest approximately $40 million in capital projects for the remainder of the fiscal year. A stock repurchase program authorized for $100 million has seen $52.6 million utilized as of March 26, 2005.
- Stock Split: A two-for-one stock split was effected on February 28, 2005.
Risks and Contingencies:
- Supply Chain Dependence: The company relies on third-party suppliers for substantially all products. Disruptions, such as the Chiron vaccine shortage, pose significant risks.
- Regulatory Environment: Subject to extensive government regulation regarding pharmaceuticals and medical devices. Changes in healthcare reform or reimbursement rates could impact demand.
- Acquisition Integration: Risks associated with integrating the Demedis Group and other recent acquisitions, including potential loss of customers or failure to achieve synergies.
- Legal Proceedings: The company faces approximately 43 product liability cases. A significant Texas class action regarding practice management software was dismissed with prejudice in April 2005 following a settlement. A New Jersey class action regarding vaccine sales was settled, though an appeal regarding attorney fees is pending.
Investor Verification Checklist
- Acquisition Impact: Verify the extent to which the 24.2% revenue growth is attributable to the Demedis Group and Ash Temple acquisitions versus organic growth.
- Vaccine Supply Chain: Monitor updates on Chiron's production capacity for the 2005 influenza season and the timeline for ID Biomedical's Fluviral FDA approval.
- Margin Sustainability: Assess whether the improved gross margin (27.8%) is sustainable given the increase in SG&A expenses (22.6% of sales).
- Working Capital: Review the timing of cash flows, as the company reported negative operating cash flow of $15.3 million despite positive net income, driven by working capital fluctuations.
- Debt Structure: Confirm the status of the $240 million convertible debt issued in 2004 and the company's ability to meet cash conversion obligations if triggered.